

11 February 2022

ReNeuron Group plc
("ReNeuron" or the "Company")

Director Change

ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Olav Hellebø is standing down as CEO and executive director of the Company and will leave the Company on 28 February 2022.

With immediate effect Iain Ross, Chairman, supported by Catherine Isted, CFO and the leadership team, will assume responsibility for the running of the business as the Company transitions to focus primarily on the development of its Exosome Technology Platform.

Olav Hellebø, commented: *"Following ReNeuron's recent change in strategy, the time has come for me to pursue other opportunities. I would like to thank employees and other stakeholders who have been instrumental in pursuing our pioneering technologies over many years."*

Iain Ross, Chairman of ReNeuron, commented: *"On behalf of the Board and Management I would like to recognise Olav's contribution to the Company over the last 7 years and wish him well in the future."*

Further announcements will be made in due course.

ENDS

Contacts:

ReNeuron

Iain Ross, Chairman
Catherine Isted, Chief Financial Officer

www.reneuron.com/investors

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)
Paul McManus/Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Company has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability through its conditionally immortalised induced pluripotent

stem cell (iPSC) platform to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Company also has a Phase 2 cell therapy candidate in retinitis pigmentosa which it plans to out-license and also has out-licensed its CTX programme in stroke disability to Fosun in China.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of the Company is Catherine Isted, Chief Financial Officer.